Review



reference cb190 wild type atcc 29213 parent strain  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC reference cb190 wild type atcc 29213 parent strain
    Bacterial strains used in this study
    Reference Cb190 Wild Type Atcc 29213 Parent Strain, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 20644 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/parent+strain+cb190/Staphylococcus+aureus+subsp%2E+aureus+Rosenbach/pmc02443886-110-55-59
    Average 99 stars, based on 20644 article reviews
    reference cb190 wild type atcc 29213 parent strain - by Bioz Stars, 2026-11
    99/100 stars

    Images

    1) Product Images from "In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿ "

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    Journal:

    doi: 10.1128/AAC.01649-07

    Bacterial strains used in this study
    Figure Legend Snippet: Bacterial strains used in this study

    Techniques Used: Variant Assay, Methylation

    Characterization of mutants from step selections undertaken with wild-type strains
    Figure Legend Snippet: Characterization of mutants from step selections undertaken with wild-type strains

    Techniques Used: Selection, Mutagenesis

    Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations
    Figure Legend Snippet: Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations

    Techniques Used:

    Related Articles

    Variant Assay:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations (rpoBR484H, gyrA L520, gyrAS84L, parCR236 duplication, and parCH103Y), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Methylation:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations (rpoBR484H, gyrA L520, gyrAS84L, parCR236 duplication, and parCH103Y), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Selection:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations (rpoBR484H, gyrA L520, gyrAS84L, parCR236 duplication, and parCH103Y), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Mutagenesis:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
    Article Snippet: Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.Table 6 also shows the doubling times for each isolate characterized when it was grown in MHII broth medium at 37°C with good aeration.. Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations (rpoBR484H, gyrA L520, gyrAS84L, parCR236 duplication, and parCH103Y), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).. The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.The significance of these findings with regard to the in vivo fitness or pathogenicity of strains exhibiting decreased susceptibility to CBR-2092 remains to be determined.



    Similar Products

    reference cb190 wild type atcc 29213 parent strain  (ATCC)
    99
    ATCC reference cb190 wild type atcc 29213 parent strain
    Bacterial strains used in this study
    Reference Cb190 Wild Type Atcc 29213 Parent Strain, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/parent+strain+cb190/Staphylococcus+aureus+subsp%2E+aureus+Rosenbach/pmc02443886-110-55-59
    Average 99 stars, based on 1 article reviews
    reference cb190 wild type atcc 29213 parent strain - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    parent strain cb190  (ATCC)
    99
    ATCC parent strain cb190
    Bacterial strains used in this study
    Parent Strain Cb190, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/parent+strain+cb190/Staphylococcus+aureus+subsp%2E+aureus+Rosenbach/pmc02443886-263-44-47
    Average 99 stars, based on 1 article reviews
    parent strain cb190 - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Bacterial strains used in this study

    Journal:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    doi: 10.1128/AAC.01649-07

    Figure Lengend Snippet: Bacterial strains used in this study

    Article Snippet: Table shows the relevant details for a series of derivatives of S. aureus ATCC 29213 (CB190) and RN4220 (CB1244) that exhibit stable resistance to agents of the rifamycin and/or quinolone classes that were isolated and characterized as described below. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Strain Relevant genotype Relevant characteristics Source or reference CB190 Wild type ATCC 29213 parent strain for isogenic strain panel ATCC CB370 rpoB H481Y Spontaneous rifampin-resistant variant of CB190 This work CB808 parC S80F Spontaneous ciprofloxacin-resistant variant of CB190 This work CB809 rpoB H481Y parC S80F Spontaneous ciprofloxacin-resistant variant of CB370 This work CB811 gyrA S84L Spontaneous nadifloxacin-resistant variant of CB190 This work CB812 rpoB H481Y gyrA S84L Spontaneous nadifloxacin-resistant variant of CB370 This work CB814 parC S80F gyrA S84L Spontaneous higher-level ciprofloxacin-resistant variant of CB808 This work CB815 rpoB H481Y parC S80F gyrA S84L Spontaneous higher-level ciprofloxacin-resistant variant of CB809 This work CB1244 Wild type RN4220 parent strain: rsbU agr , restriction negative, methylation plus laboratory strain I. Chopra CB1522 rpoB H481Y Spontaneous rifampin-resistant variant of CB1244 This work Open in a separate window Bacterial strains used in this study Isolation and characterization of resistant mutants.

    Techniques: Variant Assay, Methylation

    Characterization of mutants from step selections undertaken with wild-type strains

    Journal:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    doi: 10.1128/AAC.01649-07

    Figure Lengend Snippet: Characterization of mutants from step selections undertaken with wild-type strains

    Article Snippet: Table shows the relevant details for a series of derivatives of S. aureus ATCC 29213 (CB190) and RN4220 (CB1244) that exhibit stable resistance to agents of the rifamycin and/or quinolone classes that were isolated and characterized as described below. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Strain Relevant genotype Relevant characteristics Source or reference CB190 Wild type ATCC 29213 parent strain for isogenic strain panel ATCC CB370 rpoB H481Y Spontaneous rifampin-resistant variant of CB190 This work CB808 parC S80F Spontaneous ciprofloxacin-resistant variant of CB190 This work CB809 rpoB H481Y parC S80F Spontaneous ciprofloxacin-resistant variant of CB370 This work CB811 gyrA S84L Spontaneous nadifloxacin-resistant variant of CB190 This work CB812 rpoB H481Y gyrA S84L Spontaneous nadifloxacin-resistant variant of CB370 This work CB814 parC S80F gyrA S84L Spontaneous higher-level ciprofloxacin-resistant variant of CB808 This work CB815 rpoB H481Y parC S80F gyrA S84L Spontaneous higher-level ciprofloxacin-resistant variant of CB809 This work CB1244 Wild type RN4220 parent strain: rsbU agr , restriction negative, methylation plus laboratory strain I. Chopra CB1522 rpoB H481Y Spontaneous rifampin-resistant variant of CB1244 This work Open in a separate window Bacterial strains used in this study Isolation and characterization of resistant mutants.

    Techniques: Selection, Mutagenesis

    Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations

    Journal:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    doi: 10.1128/AAC.01649-07

    Figure Lengend Snippet: Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations

    Article Snippet: Table shows the relevant details for a series of derivatives of S. aureus ATCC 29213 (CB190) and RN4220 (CB1244) that exhibit stable resistance to agents of the rifamycin and/or quinolone classes that were isolated and characterized as described below. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Strain Relevant genotype Relevant characteristics Source or reference CB190 Wild type ATCC 29213 parent strain for isogenic strain panel ATCC CB370 rpoB H481Y Spontaneous rifampin-resistant variant of CB190 This work CB808 parC S80F Spontaneous ciprofloxacin-resistant variant of CB190 This work CB809 rpoB H481Y parC S80F Spontaneous ciprofloxacin-resistant variant of CB370 This work CB811 gyrA S84L Spontaneous nadifloxacin-resistant variant of CB190 This work CB812 rpoB H481Y gyrA S84L Spontaneous nadifloxacin-resistant variant of CB370 This work CB814 parC S80F gyrA S84L Spontaneous higher-level ciprofloxacin-resistant variant of CB808 This work CB815 rpoB H481Y parC S80F gyrA S84L Spontaneous higher-level ciprofloxacin-resistant variant of CB809 This work CB1244 Wild type RN4220 parent strain: rsbU agr , restriction negative, methylation plus laboratory strain I. Chopra CB1522 rpoB H481Y Spontaneous rifampin-resistant variant of CB1244 This work Open in a separate window Bacterial strains used in this study Isolation and characterization of resistant mutants.

    Techniques:

    Bacterial strains used in this study

    Journal:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    doi: 10.1128/AAC.01649-07

    Figure Lengend Snippet: Bacterial strains used in this study

    Article Snippet: Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).

    Techniques: Variant Assay, Methylation

    Characterization of mutants from step selections undertaken with wild-type strains

    Journal:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    doi: 10.1128/AAC.01649-07

    Figure Lengend Snippet: Characterization of mutants from step selections undertaken with wild-type strains

    Article Snippet: Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).

    Techniques: Selection, Mutagenesis

    Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations

    Journal:

    Article Title: In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus ▿

    doi: 10.1128/AAC.01649-07

    Figure Lengend Snippet: Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations

    Article Snippet: Interestingly, the doubling time of the terminal day 26 isolate (CB1884), which bears five mutations ( rpoB R484H , gyrA Δ L520 , gyrA S84L , parC R236 duplication, and parC H103Y ), is 65 min and is thus significantly longer than that of parent strain CB190 (ATCC 29213) (38 min).

    Techniques: